medigraphic.com
ISSN 0188-2198 (Impreso)

2013, Número S1

<< Anterior

Rev Mex Cardiol 2013; 24 (S1)


II. Guía de Tratamiento Farmacológico de las Dislipidemias para el primer nivel de atención

López MJ, Kuri MP, Durán FLR, Velasco GM, Ruiz PSGM, Arriola PMA, O’shea CGJ, González RJF

Idioma: Español
Referencias bibliográficas: 70
Paginas: 23-37
Archivo PDF: 200.18 Kb.


FRAGMENTO

Con la colaboración de representantes: Clínica de Prevención del Riesgo Coronario, Sociedad Mexicana de Cardiología Preventiva, Asociación Mexicana para la prevención de la Aterosclerosis y sus complicaciones, Hospital General de México, Instituto Mexicano del Seguro Social, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Colegio Nacional de Especialistas en Medicina Integrada, Instituto Nacional de Ciencias Médicas y Nutrición «Salvador Zubirán».


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Aguilar Salinas CA, Gómez Pérez FJ, Lerman I, Pérez O, Posadas C. Diagnóstico y tratamiento de las dislipidemias; posición de la Sociedad Mexicana de Nutrición y Endocrinología. Revista de Endocrinología y Nutrición. 2004; 12: 7-41.

  2. Aguilar-Salinas CA, Mehta R, Rojas R, Gómez-Pérez FJ, Olaiz G, Rull JA. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. Current Diabetes Reviews. 2005; 1: 145-158.

  3. Alcocer L, Parra JZ, Hernández HH. Versión minimalista del tratamiento antihipertensor. Rev Mex Cardiol. 2008; 19 (1): 3-6.

  4. American Diabetes Association. Magament of dyslipidemia in adults with diabetes. Diabetes Care. 2003; 26: S83-S86.

  5. American Diabetes Association Standards of Medical Care in Diabetes—2011. Diabetes Care January. 2011; 34: S11-S61. doi:10.2337/dc11-S011.

  6. American Dietetic Association: use of nutritive and nonnutritive sweeteners (position statement). J Am Diet Assoc. 1993; 93: 816-821.

  7. American Heart Association and the American Diabetes Association. Diabetes Care. 2007; 30 (1):

  8. American Heart Association Nutrition Committee; Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006; 114 (1): 82-96.

  9. Appel LJ, Moore TJ, Obarzanek E et al. For the DASH collaborative research group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997; 336: 1117-1124.

  10. Ariyo AA, Thach C, Tracy R. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003; 349 (22): 2108-2115.

  11. Ballantyne CM, Abe Y. Inflammation and lipid-lowering treatment. Curr Cardiol Rep. 1999; 1 (3): 251-255.

  12. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003; 163 (5): 553-564.

  13. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin versus simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008; 101 (10): 1428-1436.

  14. Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab. 2000; 85 (6): 2089-2112.

  15. Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif JC, Brener SJ, ASTEROID Investigators et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008; 117 (19): 2458-2466.

  16. Barriguete-Meléndez JA, Aguilar-Salinas CA, Barquera S, Pérez A, Lara A, Hernández-Ávila M et al. Motivación y Adherencia al tratamiento a largo plazo. Enfermedad crónica: dislipidemias algorritmo 1 conocer. 2 hacer y 3 evaluar. En: S Barquera, Campos I (Eds). Dislipidemias, epidemiología, evaluación y adherencia y tratamiento. Cuernavaca, México: INSP: 2007: en prensa.

  17. Burt VL, Cutler JA, Higgins M et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult us population: data from the health examination surveys 1960 to 1991. Hypertension. 1995; 26: 60-69.

  18. Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994; 308 (6923): 235-2346.

  19. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-EA, Barquera S, Rosas PM, Hernández AM et al. Las enfermedades crónico-degenerativas: un reto al sistema de salud con alternativas de solución, la “prevención clínica”. Salud Pública 2008; 5: 419-427.

  20. Du X, Cruickshank K, McNamee R et al. Case control study of stroke and the quality of hypertension control in Northwest England. BMJ. 1997; 314: 272-276.

  21. European Society of Hypertension, European Society of Cardiology. 2007 guidelines for the management of arterial hypertension. European Heart Journal. 2007; 28: 1462-1536.

  22. Guía de ejercicios para la prevención de padecimientos crónicos degenerativos para personas de 51 a 70 años. Secretaría de Salud. Salud 2000. Promoción de la Salud.

  23. Guyatt GH, Sackett DI, Sinclair JC, Hayward R, Cook DJ, Hayward R et al. For the medical literature. IX. A method for grading health care recommendations. JAMA. 1995; 274: 1800-1804.

  24. Hall WD, Ferrario CM, Moore MA et al. Hypertension-related morbidity and mortality in the Southeastern United States. Am J Med Sci. 1997; 313: 195-206.

  25. Haynes RB et al. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996; 348: 383-386.

  26. III Consenso Nacional de Hipertensión Arterial Sistémica. Rev Mex Cardiol. 2005; 16 (1): 5-47.

  27. Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, Ballantyne CM. Impact of evidence-based “clinical judgment” on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch Intern Med. 2000; 160 (9): 1361-1369.

  28. Córdova VJA, Barriguete MJA, Esqueda AL, Barquera S, Rosas PM, Hernández AM et al. Las enfermedades crónicas no transmisibles en México: sinopsis epidemiológica y prevención integral. Salud Pública de México. 2008; 50 (5).

  29. Kaplan N. Clinical hypertension. 6th edition. Baltimore Md. USA: Williams and Wilkins; 1994.

  30. Lara Esqueda A, Aroch Calderón A, Jiménez RA, Arceo Guzmán M, Velázquez Monroy O. Grupos de ayuda mutua: Estrategia para el control de diabetes e hipertensión arterial. Archivos de Cardiología de México. 2004; 74 (4): 330-336.

  31. Lazarus JM, Bourgoignie JJ, Buckalew VM et al. For the modification of diet in renal disease study group. Achievement and safety of a low blood pressure goal in chronic renal disease: the modification of diet in renal disease study group. Hypertension. 1997; 29: 641-650.

  32. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA. 1996; 275: 1557-1562.

  33. Luepker RV, McGovern PG, Sprafka JM, Shahar E, Doliszny KM, Blackburn H. Unfavorable trends in the detection and treatment of hypertension: the Minnesota heart survey (abstract). Circulation. 1995; 91: 938.

  34. Rubio MA, Moreno C, Cabrerizo YL. Guías para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). Endocrinol Nutr. 2004; 51 (5): 254-265.

  35. Manual de todo corazón. Ejercicios para la prevención de afecciones cardiovasculares e hipertensión arterial para personas de 30 a 50 años de edad. Secretaría de Salud. Dirección General de Promoción de la Salud.

  36. Velázquez MO, Barinagarrementería AF, Rubio GA, Verdejo J, Méndez BM, Violante R et al. Morbilidad y mortalidad de la enfermedad isquémica del corazón y cerebrovascular en México, 2005. Archivos de Cardiología de México. 2007; 77 (1): 31-39.

  37. MRC working party. Medical Research Council trial of treatment of mild hypertension. Principal results. BMJ. 1985; 291: 97-104.

  38. National Cholesterol Education Program High Blood Cholesterol. ATP III guidelines At-A-glance quick desk reference. NIH Publication No. 01-3305. May 2001.

  39. National Heart, lung, and blood institute. The sports guide: NHLBI Planning guide for cardiovascular risk reduction projects at sporting events. Department of Health and Human Services, National Institutes of Health; NIH publication No. 95-3802. 1995.

  40. National High Blood Pressure Education Program Working Group. National High Blood pressure Education program working group report on hypertension in the elderly. Hypertension. 1994; 23: 275-285.

  41. National High Blood Pressure Education Program. Working Group Report on Primary Prevention of Hypertension. Deparment of Health and Human Services. National Institutes of Health; NIH Publication No 93-2669. 1993.

  42. Neaton JD, Grimm RH Jr, Prineas RS et al. For the treatment of mild hypertension study research Group. Treatment mild hypertension study: Final results. JAMA. 1993; 270: 713-724.

  43. Neispeira Blanco A. 1,000 ejercicios de preparación física. 2a edición. Lleida, España: p. 204.

  44. Nesselroad JM, Flacco VA, Phillips DM, Kruse J. Accuracy of automated finger blood pressure devices. Fam Med. 1996; 28: 189-192.

  45. Norma Oficial Mexicana NOM-037-SSA2-2009, Para la prevención, tratamiento y control de las dislipidemias.

  46. Normas técnicas “dislipidemias”. Gobierno de Chile. División de salud de las personas, Departamento de Programas de las Personas. Programa Salud del Adulto. 2000.

  47. Noyes MA. Pharmacotherapy for elderly women. J Am Med Women’s Assoc. 1997; 52: 138-158.

  48. Troyo BP. Obesidad y dislipidemias. Gac Méd Méx. 2004; 140 (Suppl. 2):

  49. Durrington P. Dyslipidaemia. Lancet. 2003; 362: 717–731.

  50. Pickering T. For an American Society of Hypertension ad hoc Panel. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens. 1995; 9: 1-11.

  51. Prisant LM, Alpert BS, Robbins CB et al. American National Standard for nonautomated sphygmomanometers: summary report. Am J Hypertens. 1995; 8: 210-213.

  52. Proyecto Muévete. Manual del personal de salud. Evaluación y orientación referente a la actividad física. OPS/OMS centros para la prevención y control de enfermedades de E.U.A.

  53. PROY-Norma Oficial Mexicana NOM-037-SSA2-2009, Para la prevención, tratamiento y control de las dislipidemias.

  54. Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G et al. Applicability of the National Cholesterol Education Program III (NCEP-III) guidelines for treatment of dyslipidemia in a noncaucasian population: A Mexican Nation-Wide Survey. Revista de Investigación Clínica. 2005; 57: 28-37.

  55. Rosas-Peralta M, Lara-Esqueda A, Pastelin-Hernández G, Velázquez-MO, Martínez-Reding J, Méndez-Ortiz A et al. Re-encuesta Nacional de Hipertensión Arterial (RENAHTA): consolidación Mexicana de los factores de riesgo cardiovascular. Cohorte nacional de seguimiento. Arch Cardiol Mex. 2005; 75: 96-111.

  56. Samperio J. Actividad física y deporte en el adulto mayor. Bases fisiológicas. 1ra ed. México.

  57. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet trialists’ Collaboration. Br Med J (Clin Res Ed). 1988; 296 (6618): 320-331.

  58. Secretaría de Salud. Programa Sectorial de Salud. 2007-2012. Disponible en: http://www.alianza.salud.Gob.mx/descargas/pdf/pns_version_completa.pdf

  59. Secretaría de Salud. Sistema de Vigilancia Epidemiológica Hospitalaria de Diabetes tipo 2. DGE-SS 2004-2006.

  60. Stamler J, Caggiula AW, Grandits GA. Chapter 12. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the multiple risk factor intervention trial. Am J Clin Nutr. 1997; 65 (suppl.): 338S-3655.

  61. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153: 598-615.

  62. The CDC diabetes cost-effectiveness group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol reduction for type 2 diabetes. JAMA. 2002; 287: 2542-2551.

  63. Trials of hypertension prevention collaborative research group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high normal blood pressure: the trials of hypertension prevention phase II. Arch Intrn Med. 1997; 157: 657-667.

  64. Tsuji I, Imai Y, Nagai K et al. Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens. 1997; 10: 409-418.

  65. Whelton PW, Applegate WB, Ettinger WH et al. Efficacy of weight loss and reduced sodium intake in the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Circulation. 1996; 94 (suppl. l): 1-178.

  66. WHO, Expert Committee on Hypertension Control. Hypertension control: report of a WHO expert committee. Technical Report Series No. 862. Geneva, Switzerland: World Health Organization; 1996.

  67. Winberg N et al. 24-H ambulatory blood pressure in 352 normal Danish subjects related to age and gender. Am J Hypertens. 1995; 8: 978-986.

  68. Rader JD. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006; 116: 3090–3100. doi:10.1172/JCI30163.

  69. Shelness GS, Ledford SA. Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly. Current Opinion in Lipidology. 2005; 16: 325–332.

  70. Farina HO. Bases para el diagnóstico y tratamiento racional. Grupo argentino para el uso racional de los medicamentos. Dislipidemias. 2001; 4 (1): 2-3.




2020     |     www.medigraphic.com